Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-α, or IFN-γ

Journal of Immunology

Volumn 162, Issue 4, 1999, Pages 1889-1895

  Choi, Chulhee ^a   Park, Joo Young ^a   Lee, Jeonggi ^a   Lim, Jung Hee ^a   Shin, Eui Cheol ^a   Ahn, Young Soo ^b   Kim, Chul Hoon ^b   Kim, Se Jong ^a   Kim, Joo Deuk ^a   Choi, Il Saing ^a   Choi, In Hong ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University Wonju College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; ASTROCYTE; AUTOIMMUNE DISEASE; BRAIN DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; FETUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ADULT; ANTIGENS, CD95; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ASTROCYTES; CELL MEMBRANE; CELLS, CULTURED; CYTOKINES; DNA FRAGMENTATION; FAS LIGAND PROTEIN; FEMALE; FETUS; HUMANS; IMMUNOGLOBULIN M; INTERFERON TYPE II; INTERLEUKIN-1; INTERLEUKIN-6; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 0344258462     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Dowling, P., W. Husar, J. Menonna, H. Donnenfeld, S. Cook, and M. Sidhu. 1997. Cell death and birth in multiple sclerosis brain. J Neurol. Sci. 149:1.
2. Dowling, P., G. Shang, S. Raval, J. Menonna, S. Cook, and W. Husar. 1996. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J. Exp. Med. 184:1513.
3. Ciusani, E., S. Frigerio, M. Gelati, E. Corsini, A. Dufour, A. Nespolo, L. La Mantia, C. Milanese, G. Massa, and A. Salmaggi. 1998. Soluble Fas (Apo-1) levels in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 82:5.
4. Nishimura, T., H. Akiyama, S. Yonehara, H. Kondo, K. Ikeda M. Kato, E. Iseki, and K. Kosaka. 1995. Fas antigen expression in brains of patients with Alzheimer-type dementia. Brain Res. 695:137.
5. Guo, Q., B. L. Sopher, K. Furukawa, D. G. Pham, N. Robinson, G. M. Martin, and M. P. Mattson. 1997. Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: involvement of calcium and oxyradicals. J. Neurosci. 17:4212.
6. Mogi, M., M. Harada, T. Kondo, Y. Mizuno, H. Narabayashi, P. Riederer, and T. Nagatsu. 1996. The soluble form of Fas molecule is elevated in parkinsonian brain tissues. Neurosci. Lett. 220:195.
7. Welier, M., K. Frei, P. Groscurth, P. Krammer, Y. Yonekawa, and A. Fontana. 1994. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J. Clin. Invest. 94: 954.
8. Sabelko, K. A., K. A. Kelly, M. H. Nahm, A. H. Cross, and J. H. Russell. 1997. Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. J. Immunol. 159:3096.
9. Moller, P., K. Koretz, F. Leithauser, S. Bruderlein, C. Henne, A. Quentmeier, and P. Krammer. 1994. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer 57:371.
10. Matsuyama, T., R. Hata, H. Tagaya, Y. Yamamoto, T. Nakajima, J. Furuyama, A. Wanaka, and M. Sugita. 1995. Fas antigen mRNA induction in postischemic murine brain. Brain Res. 657:342.
11. Watanabe-Fukunaga, R., C. I. Brannan, N. Itoh, S. Yonehara, N. G. Copeland, N. A. Jenkins, and S. Nagata. 1992. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol. 148:1274.
12. Bonetti, B., and C. S. Raine. 1997. Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann. Neurol. 42:74.
13. Bonetti, B., J. Pohl, Y-L. Gao, and C. S. Raine. 1997. Cell death during autoimmune demyelination: effector but not target cells are eliminated by apoptosis. J. Immunol. 159:5733.
14. Kondo, Y., N. Ogawa, M. Asanuma, Z. Ota, and A. Mori. 1995. Regional differences in late-onset iron deposition, ferritin, transferrin, astrocyte proliferation, and microglial activation after transient forebrain ischemia in rat brain. J. Cereb. Blood Flow Metab. 15:216.
15. Rufer, M. 1996. Regulation of connexin-43, GFAP, and FGF-2 is not accompanied by changes in astroglial coupling in MPTP-lesioned, FGF-2-treated parkinsonian mice. J. Neurosci. Res. 46:606.
16. D'Souza, S. D., B. Bonetti, V. Balasingam, N. R. Cashman, P.A. Barker, A. B. Troutt, C. S. Raine, and J. P. Antel. 1996. Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J. Exp. Med. 184:2361.
17. Saas, P., P. R. Walker, M. Hahne, A. L. Quiquerez., V. Schnuriger, G. Perrin, L. French, E. G. Van Meir, N. de Tribolet, J. Tschopp, and P. Y. Dietrich. 1997. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest. 99:1173.
18. Weller, M., P. Kleihues, J. Dichgans, and H. Ohgaki. 1998. CD95 ligand: lethal weapon against malignant glioma? Brain Pathol. 8:285.
19. Gratas, C., Y. Tohma, E. G. Van Meir, M. Klein, M. Tenan, N. Ishii, O. Tachibana, P. Kleihues, and H. Ohgaki. 1997. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 7:863.
20. Husain, N, E. A. Chiocca, N. Rainov, D. N. Louis, and N. T. Zervas. 1998. Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol. 95:287.
21. Tachibana, O., J. Lampe, P. Kleihues, and H. Ohgaki. 1996. Preferential expression of Fas/APO1 (CD95) and apoptotic cell death in perinecrotic cells of glioblastoma multiforme. Acta Neuropathol. 92:431.
22. Tohma, Y., C. Gratas, E. G. Van Meir, I. Desbaillets, M. Tenan, O. Tachibana, P. Kleihues, and H. Ohgaki. 1998. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J. Neuropathol. Exp. Neurol. 57:239.
23. Osborn, L., S. Kunkel, and G. J. Nabel. 1989. Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. Proc. Natl. Acad. Sci. USA 86:2336.
24. Williams, N. 1997. Thyroid disease: a case of cell suicide? Science 275:926.
25. Ortiz-Arduan, A., T. M. Danoff, R. Kalluri, S. Gonzalez-Cuadrado, S. L. Karp, K. Elkon, J. Egido, and E. G. Neilson. 1996. Regulation of Fas and Fas ligand expression in cultured murine renal cells and in the kidney during endotoxemia. Am. J. Physiol. 271:F1193.
26. Kang, S-M., D. B. Schneider, Z. Lin, D Hanahan, D. A. Dichek, P. G. Stock, and S. Baekkeskov. 1997. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Medicine. 3:738.
27. Takahashi, T., M. Tanaka, J. Inazawa, T Abe, T. Suda, and S. Nagata. 1994. Human Fas ligand: gene structure, chromosomal location and species specificity. Int. Immunol. 6:1567.
28. Becher, B., S. D. D'Souza, A. B. Troutt, and J. P. Antel. 1998. Fas expression on human fetal astrocytes without susceptibility to fas-mediated cytotoxicity. Neuroscience 84:627.
29. Sun, D., J. N. Whitaker, L. Cao, Q. Han, S. Sun, C. Coleclough, J. Mountz, and T. Zhou. 1998. Cell death mediated by Fas-FasL interaction between glial cells and MBP-reactive T cells. J. Neurosci. Res. 52:458.
30. Hueber, A. O., M. Zornig, D. Lyon, T. Suda, S. Nagata, and G. I. Evan. 1997. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science 14: 278: 1305.
31. Wiley, S. R., K. Schooley, P. J. Smolak, W. S. Din, C. P. Huang, J. K. Nicholl, and G. R. Sutherland. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673.
32. Pan, G., J. Ni, Y-F. Wei, G-I. Yu, R. Gentz, and V. M. Dixit. 1997. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277: 815.
33. Sheridan J, P., S. A. Marsters, R. M. Pitti, A. Gurney, M. Skubatch, D. Baldwin, L. Ramakrishnan, C. L. Gray, K. Baker, W. I. Wood, et al. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818.
34. Pan, G., K. O'Rourke, A. M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni, and V. M. Dixit. 1997. The receptor for the cytotoxic ligand TRAIL. Science 276: 111.
35. Degli-Esposti, M. A., W. C. Dougall, P. J. Smolak, J. Y. Waugh, C. A. Smith, and R. G. Goodwin. 1997. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet remains an incomplete death domain. Immunity 7:813.